China Resources Boya Bio-pharmaceutical Group (300294) Fundamentals 2026 — Revenue Analysis | SniperIQ
China Resources Boya Bio-pharmaceutical Group (300294) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥7.6B, trading at ¥15.13 on the SHZ. This SniperIQ fundamentals page covers China Resources Boya Bio-pharmaceutical Group's valuation, profitability (net margin 0.2%), revenue (¥2.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is China Resources Boya Bio-pharmaceutical Group's market cap?
China Resources Boya Bio-pharmaceutical Group (300294) has a market capitalization of approximately ¥7.6B, trading at ¥15.13 on the SHZ. Market cap moves with the live share price.
What is China Resources Boya Bio-pharmaceutical Group's P/E ratio?
China Resources Boya Bio-pharmaceutical Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is China Resources Boya Bio-pharmaceutical Group?
China Resources Boya Bio-pharmaceutical Group runs a net profit margin of 0.2%, a gross margin of 47.0%, and an operating margin of -5.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does China Resources Boya Bio-pharmaceutical Group generate?
China Resources Boya Bio-pharmaceutical Group reported revenue of ¥2.0B for fiscal year 2025, with net income of ¥113M and earnings per share (EPS) of 0.22. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does China Resources Boya Bio-pharmaceutical Group pay a dividend?
China Resources Boya Bio-pharmaceutical Group offers a trailing dividend yield of about 1.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is China Resources Boya Bio-pharmaceutical Group financially healthy?
China Resources Boya Bio-pharmaceutical Group carries a debt-to-equity ratio of 0.03x and a current ratio of 6.32x, with a market beta of 0.19. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is China Resources Boya Bio-pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For China Resources Boya Bio-pharmaceutical Group (300294) the key facts are: market cap ¥7.6B, revenue ¥2.0B, 52-week range 13.64-27.99. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track China Resources Boya Bio-pharmaceutical Group's full fundamentals live
Get China Resources Boya Bio-pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.